The anti-obesity drug market has the potential to be massive, with multiple analysts projecting it may reach at least $100 billion by 2030. As a result, many top healthcare companies are vying for a piece of the market, as doing so could generate significant revenue and profit growth. Pfizer (NYSE: PFE) has been one of … Read more
Ascletis is taking a low and slow approach to oral GLP-1 dose titration in a phase 2a test after getting a look at clinical data. The latest results show a high starting dose, fast titration model provides the same weight loss and worse tolerability than more measured approaches.
Rationale: Alcohol use disorder (AUD) remains a major public health challenge, yet effective pharmacotherapies are limited. As such, there is growing interest in repurposing medications with novel mechanisms of action. Glucagon-like peptide-1 (GLP-1) receptor agonists, originally developed for type 2 diabetes, have emerged as promising candidates due to effects on intake regulation and reward processing. … Read more
Injectable drugs like Ozempic and Mounjaro have become household names in the fight against obesity and type 2 diabetes. But for all their popularity, needles aren’t everyone’s favorite. Now, a new contender is stepping into the spotlight. It’s called Orforglipron, and it’s a daily weight loss pill that could be a game-changer in how we … Read more
Jamie Mafdali of South Florida was hit with a cancer double-whammy three years ago. Shortly after her mother began treatment for breast cancer and learned it had metastasized, Mafdali herself was diagnosed with invasive ductal carcinoma in her left breast. Given her family history, Mafdali, now 45, decided to get a bilateral mastectomy. Although she … Read more
What You Should Know: – Wondr Health, a leader in digital, evidence-based lifestyle support and behavior-change interventions for weight and obesity management, has announced expansions to its comprehensive metabolic health programs. – These expansions aim to help employers prevent and manage common and expensive weight-related chronic health conditions, while also mitigating the financial risks associated … Read more
Compounded Ozempic and Wegovy, cheaper generic versions of the weight-loss drugs, can no longer be sold. Doctor explains options for patients on the drugs.
Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment Wegovy, Novo Nordisk has asked the FDA to approve it.
The U.S. Food and Drug Administration and the pharmaceutical company Novo Nordisk are urging consumers to be on the lookout for counterfeit Ozempic (semaglutide) and to refrain from using the imitation drugs.
As the FDA cracks down on compounded GLP-1 drugs like semaglutide and tirzepatide, the market for GLP-1 supplements is taking off. But do these products work?